You are here

Mitochondrial DNA repair agents for acute lung injury

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R44HL114225-02
Agency Tracking Number: R44HL114225
Amount: $3,196,272.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: NHLBI
Solicitation Number: PA14-071
Timeline
Solicitation Year: 2014
Award Year: 2015
Award Start Date (Proposal Award Date): 2015-07-16
Award End Date (Contract End Date): 2019-01-31
Small Business Information
4526 KINGSWOOD DR
Mobile, AL 36608-2814
United States
DUNS: 968503164
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 GLENN WILSON
 (251) 423-2059
 gwilson@southalabama.edu
Business Contact
 GLENN WILSON
Phone: (251) 423-2059
Email: gwilson@southalabama.edu
Research Institution
N/A
Abstract

DESCRIPTION provided by applicant Attempts to develop drug treatments for acute lung injury ALI and the acute respiratory distress syndrome ARDS have been marred by unfulfilled expectations Such failures often attributed to the heterogeneous pathophysiology of ALI ARDS and uncertainty about molecular targets of drug action have combined to fuel considerable skepticism about future drug development efforts for these currently untreatable disorders Against this background Exscienandapos s Phase I project was based on two decades of NIH supported research showing that mtDNA functions as a unique molecular sentinel controlling cytoxic response to oxidant stress To extend this concept to the point of clinical application we constructed fusion proteins directing DNA repair enzymes to mitochondria and found in multiple animal models that pharmacologic enhancement of mtDNA repair suppressed and reversed ALI Our plan for clinical introduction of the fusion proteins focusing on their inaugural use in lung transplant is solidly supported by Phase I results and conceptually buttressed by two interrelated considerations First administration of the fusion proteins to donor lungs during procurement will eliminate the requirement for treatment of the recipient and reduce the cost and time for clinical studies And second and most importantly a common complication of lung transplant primary graft dysfunction PGD related to lung ischemia reperfusion injury is similar to ALI ARDS suppression of PGD by the fusion proteins will unambiguously support their use in such oxidant stress disorders We now propose two aims intended to Determine the safety disposition and efficacy of mt targeted DNA repair enzyme in a porcine model of lung transplant and PGD and Verify in ex vivo perfused human lungs the bioequivalence safety and efficacy of the mt targeted DNA repair enzyme in comparison to approved methods of lung preservation Collectively these studies will advance Exscienandapos s mt targeted DNA repair enzymes towards FDA clearance as a device or drug for use in lung transplant where it is expected to increase the number of lungs available for transplant and reduce the incidence and severity of PGD These studies also will position Exscien for a near term submission of IND to pursue testing in ALI ARDS PUBLIC HEALTH RELEVANCE Studies are proposed in this Phase II SBIR application to prosecute clinical application of a recently developed fusion protein targeting a DNA repair enzyme to mitochondria for treatment for acute lung injury A two step experimental strategy is presented wherein the first set of experiments will verify the efficacy and safety and evaluate the
biodistribution of the fusion protein in a porcine model of lung transplant while the second set addresses the same issues in ex vivo perfused human lungs The outcome of these experiments will lead to a new device or drug capable of increasing the number of transplantable lungs and suppressing transplanted related primary graft dysfunction

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government